Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07594119 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Study acronym: FOCUS 2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 11 to 13
    • Eligibility criteria expanded, about 16 words
  2. Trial sites expanded: 6 → 11 locations
    • Start date: Aug 2026 to Sep 2026
    v8
  3. Start date: Jun 2026 to Aug 2026
    • Study sites: 5 to 6
    v7
  4. Re-verified, no change to tracked fieldsv6
  5. Study sites: 3 to 5v5
  6. Study sites: 2 to 3v4
  7. Recruitment opened
    • Study sites: 1 to 2
    v3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: May 2026 to Jun 2026
    v2
  9. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Trial Details
NCT Number NCT07594119
Lead Sponsor Rapport Therapeutics Inc.
Conditions
(from sponsor)		 Focal Seizure, Epilepsy, Focal Epilepsy
Related terms Epilepsies, Partial, Epilepsy, Seizures
Enrollment 312 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov